| Not Yet Recruiting | Tolerance, Safety, Efficacy, and Pharmacokinetics of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) NCT07273396 | Seoul National University Hospital | Phase 1 / Phase 2 |
| Recruiting | A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) NCT07213804 | Eli Lilly and Company | Phase 3 |
| Recruiting | Efficacy of Intraoperative Use of 20% Albumin Combined With Ringer Lactate Versus Ringer Lactate During Cytore NCT06351475 | Assistance Publique - Hôpitaux de Paris | N/A |
| Recruiting | Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers NCT06906341 | Corcept Therapeutics | Phase 2 |
| Unknown | SUROVA - Surgery in Ovarian Cancer, Comparing Primary and Interval Cytoreductive Surgery NCT06223763 | Clinica Universidad de Navarra, Universidad de Navarra | — |
| Active Not Recruiting | AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Can NCT05617755 | Arsenal Biosciences, Inc. | Phase 1 |
| Active Not Recruiting | Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colo NCT05185947 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian NCT05257408 | Corcept Therapeutics | Phase 3 |
| Unknown | Preoperative Systemic Therapy for Colorectal Cancer Peritoneal Metastases NCT05353582 | Sun Yat-sen University | Phase 2 |
| Terminated | A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors NCT05194072 | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 |
| Recruiting | MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO) NCT04111978 | Swiss GO Trial Group | Phase 3 |
| Active Not Recruiting | Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal De NCT04498117 | CanariaBio Inc. | Phase 3 |
| Active Not Recruiting | Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the Fir NCT03740165 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cance NCT01932125 | Hoffmann-La Roche | Phase 4 |
| Completed | Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of M NCT03593681 | Boston Scientific Corporation | — |
| Completed | PIPAC for Peritoneal Metastases of Colorectal Cancer NCT03246321 | Koen Rovers | Phase 2 |
| Unknown | EDMONd - Elemental Diet in Bowel Obstruction NCT03150992 | Royal Surrey County Hospital NHS Foundation Trust | N/A |
| Recruiting | Development of a Cinical and Biological Database in Ovarian, Fallopian Tube and Peritoneal Cancers NCT03976999 | Institut du Cancer de Montpellier - Val d'Aurelle | N/A |
| Active Not Recruiting | Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases NCT02758951 | Koen Rovers | Phase 2 / Phase 3 |
| Completed | A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Partici NCT03038100 | Hoffmann-La Roche | Phase 3 |
| Completed | Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer NCT02903771 | Kazia Therapeutics Limited | Phase 1 |
| Completed | Treatment of Peritoneal Carcinomatosis With Pressurized IntraPeritoneal Aerosol Chemotherapy - NCT03287375 | Michael Bau Mortensen | Phase 2 |
| Completed | Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors NCT02658214 | AstraZeneca | Phase 1 |
| Active Not Recruiting | PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer NCT02571725 | New Mexico Cancer Research Alliance | Phase 1 / Phase 2 |
| Completed | Effect of Outpatient Symptom Management on Gynecologic Oncology Patients Receiving Chemotherapy NCT02786524 | University of Michigan | N/A |
| Unknown | DNA Single Nucleotide Polymorphisms as Predictors of Toxicity NCT02478476 | OvaGene Oncology, Inc. | — |
| Completed | Palliative Care in Improving Quality of Life in Patients With High Risk Primary or Recurrent Gynecologic Malig NCT02578888 | Albert Einstein College of Medicine | N/A |
| Completed | Adjuvant HIPEC in High Risk Colon Cancer NCT02231086 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Phase 3 |
| Completed | HIPEC For Peritoneal Surface Malignancies Including Carcinomatosis or Sarcomatosis - Data Registry NCT02082886 | Edward-Elmhurst Health System | — |
| Completed | Local mEHT + TCM Versus Intraperitoneal Chemoinfusion in Treatment of Malignant Ascites: Phase II RCT NCT02638051 | Galenic Research Institute Ltd | Phase 2 |
| Completed | A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatme NCT01846611 | Janssen Research & Development, LLC | Phase 3 |
| Terminated | Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer NCT01681368 | National Cancer Institute (NCI) | Phase 2 |
| Completed | An Observational Study of Avastin (Bevacizumab) in Combination With Carboplatin/Paclitaxel in First Line in Pa NCT01697488 | Hoffmann-La Roche | — |
| Completed | A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Re NCT01478685 | Celgene | Phase 1 |
| Completed | Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients Wit NCT01462890 | AGO Study Group | Phase 3 |
| Completed | Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy NCT01384253 | Orano Med LLC | Phase 1 |
| Completed | BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallop NCT01314105 | Boehringer Ingelheim | Phase 1 |
| Withdrawn | Comparison of Traditional and Echocardiography Guided Fluid Management During Cytoreductive Surgery With HIPEC NCT01225757 | University of Nebraska | N/A |
| Completed | LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Tr NCT01015118 | Boehringer Ingelheim | Phase 3 |
| Completed | A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallo NCT00698451 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 2 |
| Completed | Pharmacokinetic, Safety and Efficacy Study of Nanoparticle Paclitaxel in Patients With Peritoneal Cancers NCT00666991 | CritiTech, Inc. | Phase 1 |
| Terminated | A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial NCT00516841 | Facet Biotech | Phase 2 |
| Completed | Quality of Life Study for Pediatric and Adult Patients Undergoing Hyperthermic Peritoneal Perfusion With Cispl NCT00502177 | M.D. Anderson Cancer Center | — |
| Completed | Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer NCT00436657 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer NCT00445549 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fal NCT00407407 | Celgene | Phase 1 |
| Completed | OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patie NCT00382811 | MEI Pharma, Inc. | Phase 3 |
| Completed | Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy NCT00318370 | Morphotek | Phase 2 |
| Terminated | A Phase II Study of Surgical Debulking With Peritonectomy and Biweekly Intraperitoneal 5FU With Systemic Oxali NCT00352755 | Washington University School of Medicine | Phase 2 |
| Completed | Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas NCT00443196 | Pierian Biosciences | Phase 2 / Phase 3 |
| Completed | Use of FACT-GOG/NTX Questionnaire in Peripheral Neurotoxicity & Validation of a French Version of This Questio NCT00517621 | ARCAGY/ GINECO GROUP | Phase 2 |
| Completed | Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube Cancers NCT00086567 | National Cancer Institute (NCI) | — |
| Completed | Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer NCT00262990 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis NCT00332696 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer NCT00317772 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Terminated | Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or NCT00288275 | Precision Therapeutics | — |
| Completed | Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunct NCT00189345 | AGO Study Group | Phase 2 |
| Completed | Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tub NCT00074867 | Pfizer | Phase 2 |
| Completed | Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis NCT00216372 | Ipsen | Phase 3 |
| Completed | Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peri NCT00063401 | Eli Lilly and Company | Phase 2 |
| Completed | Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response NCT00103545 | AGO Study Group | Phase 1 / Phase 2 |
| Completed | OVCA-NAC-P2: Study of Chemotherapy Followed by Cytoreductive Surgery for Ovarian, Tubal and Peritoneal Cancers NCT00112086 | Japan Clinical Oncology Group | Phase 2 |
| Completed | Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary P NCT00183794 | University of Southern California | Phase 2 |
| Completed | An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemot NCT00191646 | Eli Lilly and Company | Phase 3 |
| Completed | A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer. NCT00191607 | Eli Lilly and Company | Phase 3 |
| Completed | EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer NCT00035100 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Phase I Study of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Escalating Dose I.P. Platinum for Ga NCT00001332 | National Cancer Institute (NCI) | Phase 1 |